Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00720096 · ClinicalTrials.gov registry record · NA
Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan
A NA study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT00720096: Clinical Trial NA study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT00720096 is a NA study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 4 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00720096, a NA study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
This pilot study will help us to determine the success of using a special technique called microarray technology to examine cancer genes in order to predict how individual women will respond to one of two therapies, liposomal doxorubicin or topotecan, and which will be more effective in treating ovarian cancer that has returned (recurrent ovarian cancer). We believe that this study may lead to a means by which microarray technology can predict the most effective treatment decision, based on the genetic characteristics of her tumor tissue, for a woman with recurrent ovarian cancer. Another purpose of this study is to determine how quickly a woman with recurrent ovarian cancer will respond to treatment (treatment response rate) and to evaluate the accuracy of the genomic predictions. Recent data suggest that microarray technology can predict a patient's response to chemotherapy; this has not yet been proven in a forward-looking study which is why we are conducting this research.
Primary Outcome
Number of patients meeting 3 week feasibility window which was set as the benchmark.
Interventions
- DRUG Topotecan
- DRUG Liposomal Doxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-10 |
| Phase | NA |
Why NCT00720096 stopped before completion
NCT00720096 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Topotecan is the first listed.
NCT00720096 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00720096 about?
NCT00720096 is a clinical study titled "Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan". This pilot study will help us to determine the success of using a special technique called microarray technology to examine cancer genes in order to predict how individual women will respond to one of two therapies, liposomal doxorubicin or topotecan, and which will be more effective in treating ova...
What is the current status of trial NCT00720096?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2008-07. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00720096?
The interventions under investigation include: Topotecan (DRUG), Liposomal Doxorubicin (DRUG).
Who is sponsoring clinical trial NCT00720096?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00720096's enrollment target sits among peer trials
4 1996th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia